World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
36983
World Ranking
9234
National Ranking
4764

Overview

Christopher G. Wood is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research focuses primarily on medicine, biochemistry, genetics, and molecular biology, with a strong emphasis on pulmonary and respiratory medicine, molecular biology, surgery, cancer research, and oncology.

Their work covers a range of topics including renal cell carcinoma treatment, renal and related cancers, cancer genomics and diagnostics, bladder and urothelial cancer treatments, testicular diseases and treatments, MRI in cancer diagnosis, and cancer immunotherapy and biomarkers.

Frequent publication venues for Wood include:

  • Journal of Clinical Oncology
  • The Journal of Urology
  • Cancers
  • British Journal of Urology
  • Clinical Cancer Research

Notable recent papers authored or co-authored by Wood are:

  • Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer, 2020, Clinical Cancer Research
  • Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma, 2020, Clinical Cancer Research
  • Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma, 2021, European Urology
  • Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma, 2021, Nature Communications
  • Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy, 2020, Cancer

Frequent collaborators include:

  • José A. Karam
  • Surena F. Matin
  • Nizar M. Tannir
  • Amishi Y. Shah
  • Pavlos Msaouel

Best Publications

  • Comprehensivemolecular characterization of clear cell renal cell carcinoma

    Chad J. Creighton;Margaret Morgan;Preethi H. Gunaratne;Preethi H. Gunaratne;David A. Wheeler

  • Epidemiology of Renal Cell Carcinoma.

    Umberto Capitanio;Karim Bensalah;Axel Bex;Stephen A. Boorjian

  • Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration

    Vitaly Margulis;Shahrokh F. Shariat;Surena F. Matin;Ashish M. Kamat

  • Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

    Jean Jacques Patard;Emmanuelle Leray;Nathalie Rioux-Leclercq;Luca Cindolo

  • The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma

    Caleb F. Davis;Christopher J. Ricketts;Min Wang;Lixing Yang

  • Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

    Naomi B. Haas;Judith Manola;Robert G. Uzzo;Keith T. Flaherty

  • Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study

    Jean Jacques Patard;Hyung L. Kim;John S. Lam;Frederick J. Dorey

  • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

    Christopher Wood;Pramod Srivastava;Ronald Bukowski;Louis Lacombe

  • Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.

    Giovanni Lughezzani;Maximilian Burger;Vitaly Margulis;Surena F. Matin

  • Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

    Lijun Zhou;Xian-De Liu;Mianen Sun;Xuesong Zhang

  • Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma.

    Michelle L. Gumz;Michelle L. Gumz;Hongzhi Zou;Pamela A. Kreinest;April C. Childs

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • Mitochondrial DNA Content: Its Genetic Heritability and Association With Renal Cell Carcinoma

    Jinliang Xing;Meng Chen;Christopher G. Wood;Jie Lin

  • Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma

    Eiji Kikuchi;Vitaly Margulis;Pierre I. Karakiewicz;Marco Roscigno

  • Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center

    Montserrat Ayala-Ramirez;Sina Jasim;Lei Feng;Shamim Ejaz

  • Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3

    Mark P. Purdue;Mattias Johansson;Diana Zelenika;Jorge R. Toro

  • Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma.

    Yohei Horikawa;Christopher G. Wood;Hushan Yang;Hua Zhao

  • Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma

    M A T Hildebrandt;J Gu;J Lin;Y Ye

  • A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy

    Tobias Klatte;Vincenzo Ficarra;Christian Gratzke;Jihad Kaouk

  • Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

    J.-J. Patard;E. Leray;N. Rioux-Leclercq;L. Cindolo

Frequent Co-Authors

Surena F. Matin
Surena F. Matin The University of Texas MD Anderson Cancer Center
Nizar M. Tannir
Nizar M. Tannir The University of Texas MD Anderson Cancer Center
Pheroze Tamboli
Pheroze Tamboli The University of Texas MD Anderson Cancer Center
Eric Jonasch
Eric Jonasch The University of Texas MD Anderson Cancer Center
Shahrokh F. Shariat
Shahrokh F. Shariat Medical University of Vienna
Jay D. Raman
Jay D. Raman Penn State Milton S. Hershey Medical Center
Yair Lotan
Yair Lotan The University of Texas Southwestern Medical Center
Xifeng Wu
Xifeng Wu Zhejiang University
Francesco Montorsi
Francesco Montorsi Vita-Salute San Raffaele University
Louis L. Pisters
Louis L. Pisters The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens up many related pathways beyond the traditional MD degree. Healthcare administration is an increasingly popular field for those interested in leadership and management within hospitals and clinics. Choosing an online degree can help reduce costs; for those comparing their options, exploring the healthcare administration degree cost is a great way to find an affordable route.

For those seeking to advance further, a cheapest online mha (Master of Healthcare Administration) can be a strategic next step. This degree is designed for working professionals and can be completed online to fit your schedule and budget.

Clinicians aiming for the highest level of practice may consider a doctorate. The cheap dnp online programs are excellent for nurses seeking advanced clinical roles, while aspiring pharmacists can look into a 3-year online pharmd to fast-track their qualifications.

These online degree pathways offer flexibility, affordability, and diverse opportunities for anyone looking to build a rewarding healthcare career in the USA.

Best Scientists Citing Christopher G. Wood

Trending Scientists

Recently Published Articles